RNAi Litigation

(1) Max-Planck, Alnylam v. Whitehead Inst., MIT, Univ. Mass & (2) Tekmira v. Alnylam & (3) Univ. Utah v. Max-Planck, Alnylam, Whitehead Inst., MIT, Univ. Mass

May 2013
S	M	T	W	T	F	S
« Apr
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Scott Lloyd J.D.

Mr. Lloyd is a USPTO registered patent attorney with several years of academic and industry experience in biotechnology and pharmaceuticals. He has published and presented on various scientific and intellectual property topics.

Credentials

J.D., Cum Laude, University of Maryland, School of Law
M.S., Tumor Biology, Georgetown University
B.S., Cum Laude, Biology, Loyola College in Maryland
Bar Member, United States Court of Appeals for the District of Columbia
Bar Member, Connecticut Superior Court
Bar Member, Maryland Court of Appeals
USPTO Reg. No. 56,650
Junior Member, American Intellectual Property Law Association

What is siRNA?

Elbashir etal. (left sidebar): "Double-stranded RNA (dsRNA) induces sequence-specific posttranscriptional gene silencing in many organisms by a process known as RNA interference (RNAi) ... 21- and 22-nt RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III–like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage ..." and "... (these) 21-nucleotide siRNA duplexes specifically suppress expression of endogenous and heterologous genes in different mammalian cell(s)..."

RNAi Litigation

Scott Lloyd J.D.

Leave a Reply